© Reuters
AstraZeneca (NASDAQ:) announced the termination of two significant Phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, from its CRYSTALIZE programme. The decision was made due to challenges with patient enrollment and lower-than-anticipated event rates.
Lokelma is a therapy known for its rapid and sustained control of potassium levels in patients with cardiorenal conditions. The STABILIZE-CKD trial was designed to assess the effects of Lokelma when used in conjunction with RAASi therapy on the progression of chronic kidney disease (CKD) in patients at risk or suffering from HK. Meanwhile, the DIALIZE-Outcomes trial aimed to evaluate the impact of Lokelma on cardiovascular outcomes related to arrhythmias among patients undergoing haemodialysis treatments.
Despite these recent setbacks, Sharon Barr, R&D executive vice-president of AstraZeneca emphasized Lokelma’s effectiveness and its established position as the leading branded potassium binder globally, approved for adult HK patients in 56 countries.
In addition to the news about the halted trials, AstraZeneca also reported last month that their PACIFIC-2 trial for lung cancer treatment with Imfinzi did not meet its primary endpoint. The goal was to improve progression-free survival among patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here